Cargando…

Combined effect of polymorphisms in type III 5-α reductase and androgen receptor gene with the risk of benign prostatic hyperplasia in Korea

We evaluated whether type III 5-alpha reductase (SRD5A3; steroid reductase 5-alpha 3) polymorphism was associated with susceptibility of benign prostate hyperplasia (BPH) and the combined effects in BPH risk between the type of short tandem repeat (STR) in SRD5A3 and the length of trinucleotide (CAG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chung Lyul, Lee, Jaegeun, Na, Yong Gil, Song, Ki Hak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Exercise Rehabilitation 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091070/ https://www.ncbi.nlm.nih.gov/pubmed/27807533 http://dx.doi.org/10.12965/jer.1632802.401

Ejemplares similares

Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model
por: Lee, Gyuok, et al.
Publicado: (2017)

Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats
por: Hwangbo, Hyun, et al.
Publicado: (2018)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Mixture of Corni Fructus and Schisandrae Fructus improves testosterone-induced benign prostatic hyperplasia through regulating 5α-reductase 2 and androgen receptor
por: Hwangbo, Hyun, et al.
Publicado: (2023)

Commentary on “Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea”
por: Shin, Yu Seob, et al.
Publicado: (2021)

Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea
por: Jo, Jung Ki, et al.
Publicado: (2021)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

Is the Expression of Androgen Receptor Protein Associated With the Length of AC Repeats in the Type III 5-α Reductase Gene in Prostate Cancer Patients?
por: Park, Jong Mok, et al.
Publicado: (2013)

Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea
por: Lee, Young Ju, et al.
Publicado: (2016)

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia
por: Tong, Yu, et al.
Publicado: (2020)

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia
por: Hata, Junya, et al.
Publicado: (2023)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer
por: Hillebrand, Ana Caroline, et al.
Publicado: (2018)

The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review
por: Vickman, Renee E., et al.
Publicado: (2020)

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats
por: Liu, Rong-Fu, et al.
Publicado: (2018)

Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis
por: Jin, Bo-Ram, et al.
Publicado: (2020)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Androgen Receptor Expression in Epithelial and Stromal Cells of Prostatic Carcinoma and Benign Prostatic Hyperplasia
por: Filipovski, Vanja, et al.
Publicado: (2017)

Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3
por: Park, Woo Yong, et al.
Publicado: (2022)

Reply to Commentary on “Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea”
por: Jo, Jung Ki, et al.
Publicado: (2021)

Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship?
por: Agamia, Naglaa F., et al.
Publicado: (2016)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancer
por: Zhang, Li, et al.
Publicado: (2016)

Benign Prostatic Hyperplasia
Publicado: (2015)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Possible mechanism of benign prostatic hyperplasia induced by androgen–estrogen ratios in castrated rats
por: Xiang-Yun, Liu, et al.
Publicado: (2010)

Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
por: Yang, Minggen, et al.
Publicado: (2021)

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
por: Liu, Zhanliang, et al.
Publicado: (2022)

Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: A double‐blinded, randomized, pilot clinical trial
por: Lee, Chung Lyul, et al.
Publicado: (2022)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia
por: Kim, Jong Min, et al.
Publicado: (2011)

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
por: Ong, Hueih Ling, et al.
Publicado: (2016)

Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase
por: Youn, Dong-Hyun, et al.
Publicado: (2016)

Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
por: Fujita, Takashi, et al.
Publicado: (2023)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d6it4g4o2mrjisbaf65rfksedc